Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM

Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placeb...

书目详细资料
Main Authors:	Fautrel, B, Kirkham, B, Pope, J, Takeuchi, T, Gaich, C, Quebe, A, Zhu, B, De La Torre, I, De Leonardis, F, Taylor, P
格式:	Journal article
语言:	English
出版:	MDPI 2019

相似书籍

Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
由: Fautrel, B, et al.
出版: (2017)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
由: Taylor, P, et al.
出版: (2019)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
由: Taylor, P, et al.
出版: (2017)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
由: Strand, V, et al.
出版: (2021)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
由: Taylor, P, et al.
出版: (2017)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
由: Keystone, E, et al.
出版: (2017)

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
由: Fautrel, B, et al.
出版: (2018)

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
由: Taylor, P, et al.
出版: (2019)

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis
由: Taylor, P, et al.
出版: (2021)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
由: Tanaka, Y, et al.
出版: (2019)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
由: Taylor, P, et al.
出版: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
由: Taylor, P, et al.
出版: (2017)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: A matching-adjusted indirect comparison
由: Fautrel, B, et al.
出版: (2020)

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study
由: Taylor, P, et al.
出版: (2017)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
由: P Emery, et al.
出版: (2020-02-01)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
由: Schlueter M, et al.
出版: (2019-06-01)

Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA
由: Van De Laar, M, et al.
出版: (2019)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
由: Weinblatt, M, et al.
出版: (2017)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
由: Emery, P, et al.
出版: (2019)

Baricitinib for the treatment of rheumatoid arthritis
由: Ivan Urits, et al.
出版: (2020-12-01)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
由: Taylor, P, et al.
出版: (2022)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
由: Taylor, P, et al.
出版: (2019)

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care
由: Moeller, B, et al.
出版: (2019)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
由: Taylor, PC, et al.
出版: (2023)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
由: Weinblatt, M, et al.
出版: (2018)

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
由: Emery, P, et al.
出版: (2017)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
由: Rosemary Akinbisehin, et al.
出版: (2024-06-01)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
由: Rieke Alten, et al.
出版: (2022-10-01)

Baricitinib exposure during pregnancy in rheumatoid arthritis
由: Giulia Costanzo, et al.
出版: (2020-01-01)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.
由: Ignacio Ortea, et al.
出版: (2016-01-01)

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
由: Tanaka, Y, et al.
出版: (2021)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
由: Yue Yang, et al.
出版: (2020-09-01)

Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
由: Vibeke Strand, et al.
出版: (2024-08-01)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
由: Taylor, P, et al.
出版: (2018)

Cost per number needed to treat and treatment cost of baricitinib versus adalimumab on rheumatoid arthritis treatment in the brazilian private healthcare system
由: Bruno Corona Prandi, et al.
出版: (2023-02-01)

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
由: Taylor, P, et al.
出版: (2022)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
由: Gerd Burmester, et al.
出版: (2020-02-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
由: E.I. Alexeeva, et al.
出版: (2009-05-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
由: E.I. Alexeeva, et al.
出版: (2009-01-01)

Adalimumab in the treatment of early rheumatoid arthritis
由: Y A Sigidin, et al.
出版: (2008-04-01)